Analyst Consensus ?
ConsensusHold28 ratings
Bullish1035.7%
Neutral1139.3%
Bearish725.0%
Globe Life Inc. · GL · FY2026 Q3 · Calendar Q4 2026
Globe Life: Premium Growth Holds as Health Margins Face Pressure
Globe Life's premium growth, capital position, and planned productivity initiatives support the operating outlook, but health-margin pressure and assumption volatility make the near-term earnings path less certain.
Reported After market closeNYSEFinancial Services
$13.04B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$4.84
Consensus $4.90
EPS surprise
-1.2%
Reported versus consensus
Reported revenue
$1.60B
Consensus $1.56B
Revenue surprise
+2.2%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-3.8%
Event window
SPY move
-1.3%
Same window
Abnormal move
-2.5%
Stock minus SPY
Volume
0.9×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
GLSPY benchmark
Ask FN2 about GL FY2026 Q3
Transcript, numbers and history already loaded
Why did GL fall 3.8% after missing EPS estimates in FY2026 Q3?What changed in GL's guidance and outlook in FY2026 Q3?Give me the bull and bear case for GL after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the analysis shifts from raised guidance and confident health growth to lower-level 2026 EPS guidance, while highlighting CMS claim-processing issues, high-severity Evri claims, and a 7% 2027 EPS growth outlook.
Guidance delta
2026 EPS guidance was reaffirmed at a lower level; the 2027 EPS outlook was raised to 7% growth. Full-year 2026 premium growth is targeted at about 6.5%.
Key takeaways
- Q3 premium revenue grew 7%, with Medicare Supplement rate increases supporting growth.
- CMS claim-processing delays and high-severity Evri claims pressured health underwriting margins.
- Management said pricing adjustments and renewal rate hikes are underway for Evri.
- Share repurchases and dividends are expected to return roughly 70% of net operating income.
- AI-enabled marketing, expense management, and new compensation structures are intended to support productivity.
Management priorities
- Improve Evri profitability through pricing adjustments and renewal rate hikes.
- Expand AI use to contain expense growth and improve marketing efficiency.
- Implement compensation changes to support agent recruitment, retention, and productivity.
- Continue share repurchases, dividends, and additional reinsurance transactions.
- Maintain capital strength, with an RBC ratio target of 300% to 320%.
Follow GL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$168.41Current
$90Low
$156Average
$200High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Oct 12, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 5, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Jul 24, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 22, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Truist Securities | Buy | Buy | Maintain | Apr 24, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 30, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 15, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Dec 19, 2022 |
| Wolfe Research | Underperform | Underperform | Maintain | Jan 21, 2022 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Apr 24, 2020 |
| B of A Securities | Buy | Buy | Maintain | Jan 23, 2020 |
| UBS | Sell | Sell | Maintain | Oct 10, 2019 |
| Goldman Sachs | Sell | Neutral | Downgrade | Sep 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Aug 11, 2017 |
| Bank of America | Underperform | Neutral | Downgrade | Nov 18, 2016 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 29, 2016 |
| Citigroup | Neutral | Neutral | Maintain | Jul 7, 2016 |
| FBR Capital | Perform | Market Perform | Maintain | Feb 8, 2016 |
| PiperJaffray | Neutral | Neutral | Maintain | Jun 2, 2015 |
| Keefe Bruyette & Woods | Perform | Market Perform | Maintain | Apr 22, 2015 |
| Sterne Agee | Neutral | Neutral | Maintain | Oct 13, 2014 |
| Scotiabank | Underperform | Sector Perform | Downgrade | Nov 22, 2013 |
| RBC Capital | Underperform | Underperform | Maintain | Jun 28, 2013 |
| Janney Capital | Neutral | Buy | Downgrade | Jun 3, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $168.41. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $197 | $165.25 | +17.0% | Oct 5, 2026 |
| Piper Sandler | Paul Newsome | $200 | $178.99 | +18.8% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $166 | $178.86 | -1.4% | Jul 10, 2026 |
| Piper Sandler | Analyst unavailable | $175 | $156.28 | +3.9% | May 26, 2026 |
| Morgan Stanley | Analyst unavailable | $181 | $155.3 | +7.5% | May 21, 2026 |
| Truist Financial | Mark Hughes | $185 | $153.55 | +9.9% | Apr 24, 2026 |
| Evercore ISI | Analyst unavailable | $157 | $144.86 | -6.8% | Feb 18, 2026 |
| Morgan Stanley | Bob Huang | $176 | $140.82 | +4.5% | Dec 15, 2025 |
| Piper Sandler | John Barnidge | $167 | $133.61 | -0.8% | Nov 21, 2025 |
| Truist Financial | Mark Hughes | $158 | $134.49 | -6.2% | Oct 24, 2025 |
| Morgan Stanley | Bob Huang | $179 | $134.91 | +6.3% | Oct 7, 2025 |
| Morgan Stanley | Analyst unavailable | $166 | $139.51 | -1.4% | Aug 5, 2025 |
| Morgan Stanley | Bob Huang | $127 | $119.38 | -24.6% | Jul 14, 2025 |
| Morgan Stanley | Analyst unavailable | $126 | $127.43 | -25.2% | Feb 28, 2025 |
| Raymond James | Wilma Burdis | $188 | $109.77 | +11.6% | Oct 15, 2024 |
| Evercore ISI | Thomas Gallagher | $95 | $104.4 | -43.6% | Sep 27, 2024 |
| Truist Financial | Mark Hughes | $90 | $90.25 | -46.6% | Jul 26, 2024 |
| CFRA | Catherine Seifert | $92 | $90.3 | -45.4% | Jul 26, 2024 |
| Piper Sandler | John Barnidge | $106 | $90.48 | -37.1% | Jul 26, 2024 |
| Morgan Stanley | Bob Huang | $65 | $81.91 | -61.4% | Jul 10, 2024 |
| Jefferies | Suneet Kamath | $90 | $81.91 | -46.6% | Jul 10, 2024 |
| Piper Sandler | John Barnidge | $110 | $82 | -34.7% | Apr 24, 2024 |
| CFRA | Catherine Seifert | $55 | $59.09 | -67.3% | Apr 12, 2024 |
| Evercore ISI | Thomas Gallagher | $75 | $49.17 | -55.5% | Apr 12, 2024 |
| Piper Sandler | John Barnidge | $86.71 | $32.8 | -48.5% | Apr 11, 2024 |
| CFRA | Catherine Seifert | $78.71 | $69.99 | -53.3% | Apr 11, 2024 |
| Evercore ISI | Thomas Gallagher | $125 | $115.99 | -25.8% | Mar 14, 2024 |
| Morgan Stanley | Analyst unavailable | $132 | $121.21 | -21.6% | Jan 10, 2023 |
| Credit Suisse | Analyst unavailable | $140 | $116.5 | -16.9% | Dec 19, 2022 |
| Morgan Stanley | Analyst unavailable | $115 | $111.6 | -31.7% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $110 | $103.02 | -34.7% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $109 | $97.31 | -35.3% | Jul 28, 2022 |
Track every rating change on GL the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGlobe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured into four key segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. Its offerings encompass whole life, term life, and other life protection plans; supplemental health benefits like Medicare supplements, critical illness, and accident policies; and both single-premium and flexible-premium deferred annuities. Founded in 1979 and headquartered in McKinney, Texas, the enterprise rebranded from Torchmark Corporation to Globe Life Inc. in August 2019.
Historical context
All GL earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| HBANP Huntington Bancshares Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.3% | Huntington maintains outlook as growth broadens and fee revenue rises |
| GL-PD Globe Life Inc. 4.25% Junior Su | FY2026 Q3 · Calendar Q4 2026 | -1.2% | — | Globe Life: Premium Growth Holds, Health Margins Face Pressure |
| HBANL Huntington Bancshares Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.8% | Huntington maintains 2027 targets as fee businesses drive growth |
| NDAQ Nasdaq, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +6.9% | Nasdaq Q3 growth stays strong as AI and always-on markets advance |
| BCS Barclays PLC | FY2026 Q3 · Calendar Q4 2026 | — | -2.7% | Barclays: growth holds, but efficiency execution remains key |
| SEIC SEI Investments Company | FY2026 Q3 · Calendar Q4 2026 | +3.8% | +1.2% | SEI Posts Broad Q3 Growth as ETFs and Alternatives Expand |
Latest beats and misses
Who reports nextBeat on EPS
- LUVFY2026 Q3 · October 21, 2026+15.6% EPS+4.3% move
- RSFY2026 Q3 · October 21, 2026+17.4% EPS-0.7% move
- CACIFY2027 Q1 · October 21, 2026+16.6% EPS-1.5% move
- WCNFY2026 Q3 · October 21, 2026+3.9% EPS+8.8% move
- KMIFY2026 Q3 · October 21, 2026+9.2% EPS+1.2% move
- TXNFY2026 Q3 · October 21, 2026+7.4% EPS+2.5% move
Missed on EPS
- GGGFY2026 Q3 · October 21, 2026-2.5% EPS-16.6% move
- GL-PDFY2026 Q3 · October 21, 2026-1.2% EPS— move
- METAFY2026 Q3 · October 21, 2026-41.4% EPS+0.5% move
- LVSFY2026 Q3 · October 21, 2026-20.9% EPS-1.7% move
- MCOFY2026 Q3 · October 21, 2026-2.6% EPS+1.2% move
- CCIFY2026 Q3 · October 21, 2026-2.5% EPS-3.1% move
Get the GL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-22T18:04:18.853295+00:00
- FN2 earnings calendar · 2026-10-22T01:23:13.354406+00:00
- Polygon adjusted daily market bars · 2026-10-22T18:10:45.805656+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-22T18:10:45.803021+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-22. For educational purposes only; not investment advice.